Mebendazole clinical pharmacology: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Mebendazole}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MEBENDAZOLE TABLET, CHEWABLE [TEVA PHARMACEUTICALS USA INC]...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Clinical Pharmacology== | |||
Following administration of 100 mg twice daily for three consecutive days, plasma levels of mebendazole and its primary metabolite, the 2-amine, do not exceed 0.03 mcg/mL and 0.09 mcg/mL, respectively. All metabolites are devoid of anthelmintic activity. In man, approximately 2% of administered mebendazole is excreted in urine and the remainder in the feces as unchanged drug or a primary metabolite. | |||
====Mode of Action==== | |||
Mebendazole inhibits the formation of the worms’ microtubules and causes the worms’ glucose depletion.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MEBENDAZOLE TABLET, CHEWABLE [TEVA PHARMACEUTICALS USA INC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=107c3ad5-6ebe-4c98-a4a8-ac36663bd6a7 | publisher = | date = | accessdate = }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MEBENDAZOLE TABLET, CHEWABLE [TEVA PHARMACEUTICALS USA INC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=107c3ad5-6ebe-4c98-a4a8-ac36663bd6a7 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 20:37, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Clinical Pharmacology
Following administration of 100 mg twice daily for three consecutive days, plasma levels of mebendazole and its primary metabolite, the 2-amine, do not exceed 0.03 mcg/mL and 0.09 mcg/mL, respectively. All metabolites are devoid of anthelmintic activity. In man, approximately 2% of administered mebendazole is excreted in urine and the remainder in the feces as unchanged drug or a primary metabolite.
Mode of Action
Mebendazole inhibits the formation of the worms’ microtubules and causes the worms’ glucose depletion.[1]
References
Adapted from the FDA Package Insert.